Literature DB >> 17765428

Evaluation of patient age as a risk factor for intraocular pressure elevation after intravitreal triamcinolone.

Dhananjay Shukla1, Nagasubramaniam Vidhya, Noela M Prasad, Rajendran Mahalakshmi, Chandarmohan Kolluru, Ramaswami Krishnadas.   

Abstract

PURPOSE: To evaluate the effect of patient age on intraocular pressure (IOP) response after intravitreal injection of triamcinolone acetonide (IVTA).
DESIGN: Interventional case series.
METHODS: A total of 164 outpatients (164 eyes) aged 21 to 80 years (mean, 56.8 years), presenting with exudative age-related maculopathy (51) or macular edema of various etiologies (113), received IVTA (4 mg/0.1 ml). The primary outcome measure was IOP elevation >21 mm Hg. Patients were re-evaluated at one week, and one, three, and six months.
RESULTS: The mean baseline IOP was 15.07 mm Hg; the mean rise was 6.6 mm Hg. IOP >21 mm Hg was observed in 42 (25.6%) patients. In the age group </=45 years, IOP rise occurred in 45% (14/31) patients, compared with 21% (28/133) of older patients (P = .006). The groups were similar in baseline IOP, IOP rise, mean time-lag to maximum IOP, and response to treatment.
CONCLUSIONS: IVTA caused more frequent IOP elevation in younger patients; other aspects of IOP response and its treatment were similar to older patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17765428     DOI: 10.1016/j.ajo.2007.04.021

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes.

Authors:  Yoshio Hirano; Takeshi Ito; Miho Nozaki; Tsutomu Yasukawa; Eiji Sakurai; Munenori Yoshida; Yuichiro Ogura
Journal:  Jpn J Ophthalmol       Date:  2009-10-22       Impact factor: 2.447

Review 2.  Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.

Authors:  John D Sheppard; Timothy L Comstock; Megan E Cavet
Journal:  Adv Ther       Date:  2016-03-17       Impact factor: 3.845

Review 3.  Current intravitreal therapy and ocular hypertension: A review.

Authors:  Aditya Sudhalkar; Alper Bilgic; Shail Vasavada; Laurent Kodjikian; Thibaud Mathis; Fransesc March de Ribot; Thanos Papakostas; Viraj Vasavada; Vaishali Vasavada; Samaresh Srivastava; Deepak Bhojwani; Pooja Ghia; Anand Sudhalkar
Journal:  Indian J Ophthalmol       Date:  2021-02       Impact factor: 1.848

Review 4.  Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis.

Authors:  Francis S Mah; Paul M Karpecki
Journal:  Ophthalmol Ther       Date:  2021-10-27

5.  Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries.

Authors:  Sarah Lebrize; Louis Arnould; Abderrahmane Bourredjem; Catharina Busch; Matus Rehak; Pascale Massin; Joao Barbosa-Breda; Marco Lupidi; Cesare Mariotti; Mahmoud Hamza; Alice Grise-Dulac; Pierre-Henry Gabrielle; Stephanie Baillif; Catherine Creuzot-Garcher
Journal:  Ophthalmol Ther       Date:  2022-04-15

6.  Incidence and risk factors for postoperative intraocular pressure response to topical prednisolone eye drops in patients undergoing phacoemulsification.

Authors:  Sharmila Rajendrababu; Srilekha Pallamparthy; Anusha Arunachalam; Mohammed Sithiq Uduman; Senthilkumari Srinivasan; S R Krishnadas; Vijayalakshmi A Senthilkumar
Journal:  Int Ophthalmol       Date:  2021-07-26       Impact factor: 2.031

7.  De novo ocular hypertension after Descemet stripping endothelial keratoplasty: comparative 3-year incidence, risk factors, and outcomes.

Authors:  Errol W Chan; Tina T Wong; Hla M Htoon; Ching L Ho; Donald T Tan; Jodhbir S Mehta
Journal:  Clin Ophthalmol       Date:  2013-09-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.